Common nonsynonymous substitutions in SLCO1B1 predispose to statin intolerance in routinely treated individuals with Type 2 diabetes: A Go-DARTS study

Common nonsynonymous substitutions in SLCO1B1 predispose to statin intolerance in routinely treated individuals with Type 2 diabetes: A Go-DARTS study

Mostra altre versioni (1)

SLCO1B1 gene variants are associated with severe statin-induced myopathy. We examined whether these variants are also associated with general statin intolerance in a large population of patients with type 2 diabetes receiving statins as part of routine clinical care. A total of 4,196 individuals wer...

Descrizione completa

Dettagli Bibliografici
Autori principali:	Donnelly, L, Doney, A, Tavendale, R, Lang, C, Pearson, E, Colhoun, H, McCarthy, M, Hattersley, A, Morris, A, Palmer, C
Natura:	Journal article
Lingua:	English
Pubblicazione:	2011

Documenti analoghi

Common nonsynonymous substitutions in SLCO1B1 predispose to statin intolerance in routinely treated individuals with type 2 diabetes: a go-DARTS study.
di: Donnelly, L, et al.
Pubblicazione: (2011)

Effect of SLCO1B1 genotypes on statin intolerance and response
di: R. Ghelani, et al.
Pubblicazione: (2022-10-01)

Loss-of-function CYP2C9 variants improve therapeutic response to sulfonylureas in type 2 diabetes: a Go-DARTS study.
di: Zhou, K, et al.
Pubblicazione: (2010)

Variation in TCF7L2 influences therapeutic response to sulfonylureas: a GoDARTs study.
di: Pearson, E, et al.
Pubblicazione: (2007)

Reduced-function SLC22A1 polymorphisms encoding organic cation transporter 1 and glycemic response to metformin: a GoDARTS study.
di: Zhou, K, et al.
Pubblicazione: (2009)

TCF7L2 in the Go-DARTS study: evidence for a gene dose effect on both diabetes susceptibility and control of glucose levels.
di: Kimber, C, et al.
Pubblicazione: (2007)

APPLIED ASPECTS OF SLCO1B1 PHARMACOGENETIC TESTING FOR PREDICTING OF STATIN-INDUCED MYOPATHY AND PERSONALIZATION OF STATINS THERAPY
di: D. A. Sychev, et al.
Pubblicazione: (2015-09-01)

APPLIED ASPECTS OF SLCO1B1 PHARMACOGENETIC TESTING FOR PREDICTING OF STATIN-INDUCED MYOPATHY AND PERSONALIZATION OF STATINS THERAPY
di: D. A. Sychev, et al.
Pubblicazione: (2015-09-01)

SLCO1B1 variants and statin-induced myopathy--a genomewide study.
di: Link, E, et al.
Pubblicazione: (2008)

THE SLCO1B1 GENE POLYMORPHISM AND STATIN-INDUCED MYOPATHY IN RUSSIAN PATIENTS
di: V. I. Petrov, et al.
Pubblicazione: (2014-10-01)

Side effects of statins in patient with compensated hypothyroidism and SLCO1B1 *5 (c.521T>C) polymorphism
di: Leonid G. Strongin, et al.
Pubblicazione: (2017-12-01)

Protective Effects of Statin Therapy in Cirrhosis Are Limited by a Common SLCO1B1 Transporter Variant
di: Melissa Merkel, et al.
Pubblicazione: (2021-10-01)

Pharmacogenetics in Type 2 diabetes: variation in TCF7L2 influences response to sulphonylureas
di: Pearson, E, et al.
Pubblicazione: (2007)

Evaluation of the effect of the carrier of polymorphic variants of the SLCO1B1 gene on efficacy and safety in patients during treatment with statins
di: N. A. Rumyantsev, et al.
Pubblicazione: (2018-02-01)

Genetic determinants of statin intolerance
di: Pollex Rebecca L, et al.
Pubblicazione: (2007-03-01)

Management of statin intolerance
di: Soma B Raju, et al.
Pubblicazione: (2013-01-01)

Creatine kinase and SLCO1B1 RS4363657 polymorphism in Malaysian dyslipidaemic patients prescribed with statin drugs
di: Meor Anuar Shuhaili, Meor Fairuz Rizal
Pubblicazione: (2016)

SLCO1B1 and SLCO1B3 genetic mutations in Taiwanese patients with Rotor syndrome
di: Ya-Yuan Cheng, et al.
Pubblicazione: (2023-07-01)

Construction and characterization of a humanized SLCO1B1 rat model with its application in evaluating the uptake of different statins
di: Yuanjin Zhang, et al.
Pubblicazione: (2024-04-01)

Role of the D76N polymorphism of insulin promoter factor-1 in predisposing to Type 2 diabetes.
di: Owen, K, et al.
Pubblicazione: (2004)

Treating statin-intolerant patients
di: Pigna G, et al.
Pubblicazione: (2011-04-01)

Large-scale type 2 diabetes association analysis of low-frequency nonsynonymous coding variants in the HNF4A gene including up to 17,600 individuals
di: Mohammadi, B, et al.
Pubblicazione: (2008)

Clinical case of statin-induced myopathy in female patient with compensated hypothyroidism and unfavorable polymorphic variant of SLCO1B1*5 (c.521T>C)
di: Liya A. Lugovaya, et al.
Pubblicazione: (2021-05-01)

Toward pharmacogenetic SLCO1B1‐guided dosing of methotrexate in arthritis using a murine Slco1b2 knockout model
di: Zachary L. Taylor, et al.
Pubblicazione: (2021-11-01)

Analysis of the association between SLCO1B1 genetic polymorphism (rs4149056) and lipid profile among statin users of HUSM, Kelantan
di: Yusri, Nur Farah Izzati
Pubblicazione: (2022)

PCSK9 Inhibitor Therapy as an Alternative for Statin Intolerance
di: K. O. Shnaider, et al.
Pubblicazione: (2023-12-01)

Treatment strategies and LDL cholesterol target attainment in patients with statin intolerance: Insights from the multicentre statin intolerance registry
di: Paulina E. Stürzebecher, et al.
Pubblicazione: (2025-03-01)

Genome bioinformatic analysis of nonsynonymous SNPs
di: Todd John A, et al.
Pubblicazione: (2007-08-01)

Scrutinizing Deleterious Nonsynonymous SNPs and Their Effect on Human POLD1 Gene
di: Md. Nazmul Islam Bappy, et al.
Pubblicazione: (2022-01-01)

Personalized approach to patients with statin intolerance based on pharmacogenomics (function of OATP1B1 protein)
di: Anja Ćuk, et al.
Pubblicazione: (2023-01-01)

Two common nonsynonymous paraoxonase 1 (<it>PON1</it>) gene polymorphisms and brain astrocytoma and meningioma
di: Martínez Carmen, et al.
Pubblicazione: (2010-08-01)

Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants.
di: Burton, P, et al.
Pubblicazione: (2007)

Associations between UGT1A1, SLCO1B1, SLCO1B3, BLVRA and HMOX1 polymorphisms and susceptibility to neonatal severe hyperbilirubinemia in Chinese Han population
di: Juan Fan, et al.
Pubblicazione: (2024-01-01)

The cholesterol-lowering effect of statins is modified by LILRB5 intolerance genotype: Results from a recruit-by-genotype clinical trial
di: Aleksi Tornio, et al.
Pubblicazione: (2023-03-01)

ABCG2 and SLCO1B1 gene polymorphisms in the Croatian population
di: Tamara Božina, et al.
Pubblicazione: (2022-11-01)

Ethylmethylhydroxypyridine Succinate Is an Inhibitor but Not a Substrate of ABCB1 and SLCO1B1
di: Aleksey V. Shchulkin, et al.
Pubblicazione: (2023-10-01)

Impact of SLCO1B1*5 on Flucloxacillin and Co-Amoxiclav–Related Liver Injury
di: Mohammad Alshabeeb, et al.
Pubblicazione: (2022-06-01)

Pharmacogenomic-guided clozapine administration based on HLA-DQB1, HLA-B and SLCO1B3-SLCO1B7 variants: an effectiveness and cost-effectiveness analysis
di: Kohei Ninomiya, et al.
Pubblicazione: (2022-10-01)

Why Do I Get Side Effects? Personalized (N-of-1) Trials for Statin Intolerance and the Nocebo Effect
di: James Philip Howard, et al.
Pubblicazione: (2022-09-01)

Hyperglycemia‐mediated oocyte TET3 insufficiency predisposes offspring to glucose intolerance
di: Xiumei Wu, et al.
Pubblicazione: (2022-10-01)